DDInter542 DDInter1201
Dicoumarol is an oral anticoagulant agent that works by interfering with the metabolism of vitamin K. In addition to its clinical use, it is also used in biochemical experiments as an inhibitor of reductases.
Metreleptin, a recombinant analog of the human hormone leptin, is an orphan drug used to treat complications of leptin deficiency in people with lipodystrophy. Lipodystrophies include a range of disorders characterized by the reduction, absence, or altered distribution of adipose tissue. Complications of lipodystrophy include metabolic abnormalities such as hypertriglyceridemia, insulin resistance, diabetes mellitus, and fatty liver disease. These metabolic abnormalities are often aggravated by excessive food intake, which is further aggravated by leptin deficiency, a protein secreted by adipose tissue. Administration of metreleptin results in improvement of metabolic symptoms including improvements in insulin resistance, reduced HbA1c and fasting glucose, reduced triglycerides, and reductions in food intake. Metreleptin is produced in _E. coli_ and differs from native human leptin by the addition of a methionine residue at its amino terminus. In February 2014, metreleptin was approved by the FDA for the treatment of complications of leptin deficiency, as an adjunct to diet, in patients with congenital generalized or acquired generalized lipodystrophy. Metreleptin was approved by Health Canada in January 2024 for the same patient population, in addition to patients with partial lipodystrophy.
Dicoumarol {u} (Compound) resembles {v} (Compound) Warfarin
Warfarin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Metreleptin
Dicoumarol {u} (Compound) resembles {v} (Compound) Phenprocoumon
Phenprocoumon {u} (Compound) resembles {v} (Compound) Warfarin
Warfarin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Metreleptin
Dicoumarol {u} (Compound) resembles {v} (Compound) Warfarin
Warfarin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metreleptin
Dicoumarol {u} (Compound) resembles {v} (Compound) Warfarin
Warfarin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ticagrelor
Ticagrelor {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Metreleptin
Dicoumarol {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Nilotinib
Nilotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Metreleptin
Dicoumarol {u} (Compound) resembles {v} (Compound) Warfarin
Warfarin {u} may lead to a major life threatening interaction when taken with {v} Dasatinib
Dasatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Metreleptin
Dicoumarol {u} (Compound) binds {v} (Gene) CRYZ
CRYZ {u} (Gene) is downregulated by {v} (Compound) Methylergometrine
Methylergometrine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Metreleptin
Dicoumarol {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metreleptin
Dicoumarol {u} (Compound) resembles {v} (Compound) Warfarin
Warfarin {u} may lead to a major life threatening interaction when taken with {v} Zanubrutinib
Zanubrutinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Metreleptin
Dicoumarol {u} (Compound) downregulates {v} (Gene) P4HTM
P4HTM {u} (Gene) is upregulated by {v} (Compound) Dasatinib
Dasatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Metreleptin
Dicoumarol (Compound) resembles Warfarin (Compound) and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Metreleptin
Dicoumarol (Compound) resembles Phenprocoumon (Compound) and Phenprocoumon (Compound) resembles Warfarin (Compound) and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Metreleptin
Dicoumarol (Compound) resembles Warfarin (Compound) and Warfarin may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Metreleptin
Dicoumarol (Compound) resembles Warfarin (Compound) and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Metreleptin
Dicoumarol (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Nilotinib (Compound) and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Metreleptin
Dicoumarol (Compound) resembles Warfarin (Compound) and Warfarin may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Metreleptin
Dicoumarol (Compound) binds CRYZ (Gene) and CRYZ (Gene) is downregulated by Methylergometrine (Compound) and Methylergometrine may cause a moderate interaction that could exacerbate diseases when taken with Metreleptin
Dicoumarol (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Metreleptin
Dicoumarol (Compound) resembles Warfarin (Compound) and Warfarin may lead to a major life threatening interaction when taken with Zanubrutinib and Zanubrutinib may cause a moderate interaction that could exacerbate diseases when taken with Metreleptin
Dicoumarol (Compound) downregulates P4HTM (Gene) and P4HTM (Gene) is upregulated by Dasatinib (Compound) and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Metreleptin